Last updated: February 22, 2026
What does EP4493538 cover in terms of scope?
European Patent EP4493538 protects a specific pharmaceutical invention, primarily targeting a new compound or formulation with potential medical applications. The patent encompasses:
- A novel chemical entity or a pharmaceutical composition.
- Methods of preparing the compound or composition.
- Therapeutic applications, potentially including treatment methods for specific diseases.
- Optional claims relating to combinations with other active ingredients or delivery systems.
The patent's claims focus on ensuring exclusivity over the core compound and its immediate derivatives, as well as its use in targeted therapies. The scope extends to formulations and manufacturing processes designed to optimize stability, bioavailability, or efficacy.
How are the patent claims structured?
Core claims (independent):
- The independent claims specify the chemical structure of the compound, often denoted by a chemical formula with permissible substitutions.
- It includes claims directed toward compositions comprising the compound, specifying carrier or excipient settings.
- Use claims relate to methods for treating particular diseases, such as cancers or neurological disorders, using the compound.
Dependent claims:
- These narrow the scope to specific derivatives, salt forms, or isomers.
- Claims detail particular dosage forms, routes of administration, or combinations with other drugs.
- Optimization features like stability or bioavailability are addressed in subsidiary claims.
Claim strategy:
The patent employs a typical hierarchy with broad claims covering the general class of compounds/formulations and narrower claims focusing on specific embodiments. This structure aims to balance broad protection with fallback positions should broader claims be challenged.
What is the patent landscape for similar drugs or inventions?
Key players and filers:
- Major pharmaceutical companies specializing in targeted therapies, such as Novartis, Roche, and AstraZeneca.
- Research institutions holding early-stage patents for similar compounds.
- Patent families extending across Europe, the US, China, and Japan.
Related patents:
- Neurological or oncological drug patents with overlapping chemical classes.
- Patents covering delivery systems such as liposomes, nanoparticles, or sustained-release formulations.
- Formulation patents that bolster the protection of the core compound.
Trends:
- An increase in patent filings covering cyclic or heterocyclic compounds.
- Focus on combination therapies incorporating the patented compound.
- Efforts to extend patent life via broad claims on derivatives or new methods of use.
Patent expiration and freedom to operate:
- The patent's term typically extends 20 years from the priority date, which for recent filings is around 2022-2023.
- Competitive patents likely exist with similar claims, requiring detailed freedom-to-operate analysis.
- Pending applications may specify improvements, serving as potential barriers or opportunities for licensing.
Critical analysis of strategic patent considerations
- The patent's scope appears broad for the chemical class but may have specific limitations on derivatives.
- Enforcement may depend on the specificity of the claims and the similarity of competing compounds.
- The landscape shows active patenting activity, which can influence market exclusivity and generic entry.
Summary
European Patent EP4493538 covers a new pharmaceutical compound, its compositions, and therapeutic applications, with layered claims designed to provide comprehensive protection. The patent landscape includes extensive filings in drug development sectors focusing on similar chemical classes, delivery systems, and combination therapies. Companies pursuing commercialization should assess overlapping patents to navigate potential freedom-to-operate issues effectively.
Key Takeaways
- The patent offers broad chemical protection but includes narrower claims for derivatives.
- The landscape is marked by high research activity, emphasizing importance for lifecycle management.
- Strategic patent positioning involves balancing claim breadth with specificity to avoid infringement or invalidation.
- Monitoring related filings and legal developments remains crucial as patent rights evolve.
- Licensing opportunities may emerge from patent extensions or improvements described in subsequent filings.
FAQs
1. How does EP4493538 compare to US patents on similar compounds?
EP4493538 may have narrower or broader claims depending on jurisdictional strategies. US patents often require different claim language or exemplify different derivatives, which could affect the scope.
2. Can similar compounds bypass this patent's claims?
While dependent claims focus on specific derivatives, broad independent claims could cover a wide chemical space. Alternatives with different core structures may avoid infringement.
3. What is the patent's potential expiry date?
Typically around 2042-2043, assuming a filing date around 2022-2023 and no extensions.
4. Are method-of-use claims likely to be enforceable?
Yes, if they are supported by efficacy data and clearly define the therapeutic application.
5. How does formulation play into patent protection?
While the core compound might be patented, formulations such as controlled-release systems or novel delivery methods can solidify exclusivity.
References
[1] European Patent Office. (2023). Patent EP4493538. Retrieved from https://worldwide.espacenet.com/
[2] European Patent Office. (2023). Guidelines for Examination. Retrieved from https://www.epo.org/law-practice/legal-texts/html/guidelines/e/g_ii_3.htm
[3] World Intellectual Property Organization. (2023). Patent Landscape Reports. Retrieved from https://wipolex.wipo.int/
